Citi opened an “upside 90-day catalyst watch” on shares of Stryker (SYK) while keeping a Buy rating on the name with a $420 price target The firm believes fundamentals in the U.S. medical technology sector remain “healthy” despite the recent volatility. Stryker has reported consistent double-digit revenue and earnings growth, the analyst tells investors in a research note.
Join thousands of traders who make more informed decisions with our premium features.
Real-time quotes, advanced visualizations, backtesting, and much more.
